TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
RANCHO CORDOVA, Calif., Sept. 27, 2017 -- Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that Dalip Sethi, Ph.D., senior director of research and development, will participate in the 2017 Cell & Gene Meeting on the Mesa, which is being held October 4-6, 2017 at the Estancia La Jolla Hotel in La Jolla, California. Dr. Sethi will present an overview of Cesca Therapeutics’ autologous cell processing capabilities on Wednesday, October 4 at 11:30am in La Jolla Ballroom 2.
For more information, please visit http://www.meetingonthemesa.com.
About the Cell & Gene Meeting on the Mesa
The Cell & Gene Meeting on the Mesa is a three-day conference combining discussions between key opinion leaders, senior executives and top academic researchers in the field of regenerative medicine. The program also includes 60+ presentations by the field’s most promising companies and poster abstracts by leading scientists from around the globe.
About Cesca Therapeutics Inc.
Cesca is a leading regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. Cesca is also leveraging its proprietary AutoXpress® technology platform to develop autologous stem cell-based therapies that address significant unmet needs in the vascular, cardiology and orthopedic markets.
Forward-Looking Statement
The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. A more complete description of risks that could cause actual events to differ from the outcomes predicted by Cesca Therapeutics' forward-looking statements is set forth under the caption "Risk Factors" in Cesca Therapeutics’ annual report on Form 10-K and other reports it files with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.
Company Contact:
Cesca Therapeutics Inc.
Wendy Samford
916-858-5191
[email protected]
Investor Contact:
Rx Communications
Paula Schwartz
917-322-2216
[email protected]
